Dr. Robby T. Ayoub, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 395
Licensed in California since 2008, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
CA license A102841 (first issued 2008; current) -
Critical Care Medicine (Internal Medicine) Physician
CA license A102841 (first issued 2008; current) -
Internal Medicine Physician
CA license A102841 (first issued 2008; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
- Providence St. Joseph Hospital Orange, CA
- Palmdale Regional Medical Center Palmdale, CA
Medical groups
- UC Regents (319 clinicians)
- Regents of the University of California (60 clinicians)
- Palmdale Intensivist Inc (16 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 395
- Services billed
- 4,432
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 1,300 | 148 |
| Test for allergy using allergenic extract | 880 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 462 | 166 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 209 | 25 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 209 | 25 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 206 | 24 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 206 | 24 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 126 | 24 |
| Test to measure expiratory airflow and volume | 115 | 63 |
| Test to measure expiratory airflow and volume initiated by patient and evaluated by provider | 114 | 65 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Huntington Beach, CA | 912 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Huntington Beach, CA | 567 |
| Montelukast Sodium Other prescribers in Huntington Beach, CA | 495 |
| Pantoprazole Sodium Other prescribers in Huntington Beach, CA | 226 |
| Prednisone Other prescribers in Huntington Beach, CA | 175 |
| Fluticasone Propionate Other prescribers in Huntington Beach, CA | 167 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Huntington Beach, CA | 153 |
| Atorvastatin Calcium Other prescribers in Huntington Beach, CA | 143 |
| Roflumilast Other prescribers in Huntington Beach, CA | 130 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Huntington Beach, CA | 130 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 168 payments worth $3,981 in total to this clinician.
| GlaxoSmithKline, LLC. | $835 |
|---|---|
| Verona Pharma, Inc. | $508 |
| AstraZeneca Pharmaceuticals LP | $475 |
| Genzyme Corporation | $365 |
| Grifols USA, LLC | $350 |
| Jazz Pharmaceuticals Inc. | $209 |
| Avadel Cns Pharmaceuticals, LLC | $207 |
| Harmony Biosciences LLC | $183 |
| Food and Beverage | $3,914 |
|---|---|
| Education | $67.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. May 9, 2025 | Education XYWAV · NEUROLOGY · in-kind | $67.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $25,165 in research payments for these studies, mostly to the institutions running them.
- An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV
Jazz Pharmaceuticals Inc. - A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC. - A prospective, real-world, interventional study to evaluate the effect
GlaxoSmithKline, LLC. - A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
Chiesi USA, Inc. · Completed · NCT05292586
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.